IP Library › Granted Patent US 12,414,941
Granted Patent B2
US 12,414,941 · App. 18/072,207 · Granted Sep 16, 2025

Low concentration delivery of an ergoline derivative for treatment of a headache

Inventors: Ralph Solarski (Alpharetta, GA); Robert Edward Malone (Northborough, MA)
Assignee: Relevale, Inc.
A61K31/437A61M5/2033A61M5/281A61M5/3202A61P25/06A61M2005/206A61M2005/3139
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,414,941
App. No.
18/072,207
Filed
Nov 30, 2022
Granted
Sep 16, 2025
Kind
B2
Art Unit
3783
USPC
604/506
Abstract

Provided are ergoline derivative containing medicaments disposed within a preassembled, prefilled, single-use delivery device, methods for administering a medicament using a preassembled, prefilled, single-use delivery device, and systems or kits that contain one or more preassembled, prefilled, single-use devices and user instructions, such as for treatment of a migraine or other headache.

Claims (18)

1. A parenteral pharmaceutical composition comprising dihydroergotamine or a pharmaceutically acceptable salt thereof at a concentration of about 1 mg/ml and one or more pH maintaining or pH adjusting agents, wherein pH of the composition is between about 3 to about 8, the composition being contained in a preassembled, prefilled, single-use delivery device that is capable of delivering a dose of between about 0.5 to about 3 mg of the dihydroergotamine or the pharmaceutically acceptable salt thereof to a patient and is not user adjustable with respect to dosage or dosing rate.

2. The composition of claim 1 , wherein the one or more pH maintaining or pH adjusting agents includes a buffer.

3. The composition of claim 1 , wherein the dihydroergotamine or the pharmaceutically acceptable salt thereof is dihydroergotamine mesylate.

4. The composition of claim 3 , wherein the dose is about 1 mg of dihydroergotamine mesylate.

5. The composition of claim 4 , wherein the single-use delivery device is an autoinjector that includes a tension spring, and a rate of dosing depends on the degree of tension in the tension spring.

6. The composition of claim 5 , wherein the tension spring has a predetermined amount of tension so as to provide a desired dosing rate.

7. The composition of claim 6 , wherein the predetermined amount of tension is preloaded.

8. The composition of claim 4 , wherein the single-use delivery device is an autoinjector that includes a dosing mechanism comprising an injection spring having a degree of compression applied thereto, and a rate of dosing that depends on the degree of compression applied to the injection spring.

9. The composition of claim 8 , wherein the degree of compression of the injection spring is predetermined so as to provide a predetermined dosing rate and is not user adjustable.

10. The composition of claim 1 , wherein the one or more pH maintaining or pH adjusting agents prevent any sudden change in pH of the composition.

11. The composition of claim 1 , wherein the single-use delivery device further comprises a trigger mechanism for actuating an actuating lever maintained under pressure in an armed position.

12. The composition of claim 1 , wherein the composition is contained in the single-use delivery device by a plunger.

13. The composition of claim 1 , wherein the composition is contained in the single-use delivery device by a plunger until activated by a trigger.

14. The composition of claim 13 , wherein the single-use delivery device further comprises a pawl member that releasably interfaces with a retainer in an armed position until the pawl member is released from the retainer by the trigger to activate the plunger.

15. The composition of claim 13 , wherein the trigger activates a piston rod depressing the plunger and delivering the dose through an injection needle.

16. The composition of claim 1 , wherein the single-use delivery device further comprises a moveable safety shield that is moveable about an injection needle to protect against inadvertent contact with the injection needle.

17. The composition of claim 1 , wherein the single-use delivery device further comprises a piston rod retained in an armed position keeping a tension spring under compression, the piston rod being in contact with a plunger, and when a trigger is actuated, the piston rod is released from its retainer and urged forward by the tension spring.

18. The composition of claim 1 , wherein the single-use delivery device further comprises a suction cup facilitating removal of a safety cap.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2022
From: SOLARSKI, RALPH ANDREW; MALONE, ROBERT EDWARD
To: RELEVALE INC.
Reel/Frame 061926/0298 →
Continuity (5)
Continuation 17841042 · Jun 15, 2022
Continuation 17365750 · Jul 1, 2021
Continuation 16359313 · Mar 20, 2019
Provisional Application 62645212 · Mar 20, 2018
Related Publication 20230091885A1 · Mar 23, 2023
References Cited (22)
US 6495535B1 · Plachetka et al. · 2002 [cited by applicant]
US 8945067B2 · McLoughlin et al. · 2015 [cited by applicant]
US 10881798B2 · Travanty · 2021 [cited by applicant]
US 11083712B1 · Solarski et al. · 2021 [cited by applicant]
US 11541043B2 · Solarski · 2023 [cited by examiner]
US 20030106824A1 · Wilmot et al. · 2003 [cited by applicant]
US 20080154200A1 · Lesch · 2008 [cited by applicant]
US 20080287451A1 · Cook et al. · 2008 [cited by applicant]
US 20100318037A1 · Young et al. · 2010 [cited by applicant]
US 20140179705A1 · Armer et al. · 2014 [cited by applicant]
US 20160235664A1 · Wotton et al. · 2016 [cited by applicant]
US 20190000753A1 · Narasimha Murthy et al. · 2019 [cited by applicant]
US 20210322392A1 · Solarski et al. · 2021 [cited by applicant]
US 20220304991A1 · Solarski et al. · 2022 [cited by applicant]
Winner, P, et al., “A Double-Blind Study of Subcutaneous Dihydroergotamine vs. Subcutaneous Sumatriptan in the Treatment of Acute Migraine.” Arc. Neurol. 1996:53(2):180-4. [cited by applicant]
“D.H.E 45 Prescribing Information” by Valeant Pharmaceuticals North America (Sep. 2009). (Year: 2009). [cited by applicant]
“Testosterone.” Glowm, Rovi Corporation, Dec. 4, 2010, web.archive.org/web/20101204095326/https ://www.glowm.com/resources/glowm/cd/pages/drugs/t014.htm (Year: 2010). [cited by applicant]
Weaver-Agostoni, J. (2013) “Cluster Headache” American Family Physician 88(2):122-8. [cited by applicant]
Matthew P., et al., “DHE: An Old Dog with New Tricks . . . Maybe?” American Headache Foundation, Aug. 18, 2015. [cited by applicant]
The Incidence and Prevalence of Cluster Headache: A Meta-Analysis of Population-Based Studies “Cephalalgia 28(6):614-8.” [cited by applicant]
Lippincott's Nursing Procedures, Fifth Edition, p. 308 (Year: 2004). [cited by applicant]
Non-Final Office Action issued for U.S. Appl. No. 17/365,750 dated Feb. 12, 2024 (10 pages). [cited by applicant]